摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-isopropyl-6-methyl-[1,2,4]triazolo[4,3-a]pyridine

中文名称
——
中文别名
——
英文名称
3-isopropyl-6-methyl-[1,2,4]triazolo[4,3-a]pyridine
英文别名
6-Methyl-3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridine
3-isopropyl-6-methyl-[1,2,4]triazolo[4,3-a]pyridine化学式
CAS
——
化学式
C10H13N3
mdl
——
分子量
175.233
InChiKey
LYWWOUPDTVDCQT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    3-甲基吡啶Isobutyraldehyde tosylhydrazone叔丁基过氧化氢 作用下, 以 癸烷二氯甲烷 为溶剂, 反应 2.5h, 以50%的产率得到3-isopropyl-6-methyl-[1,2,4]triazolo[4,3-a]pyridine
    参考文献:
    名称:
    I 2 -TBHP催化一锅高效合成,从N-甲苯磺酰hydr和芳族N-杂环通过分子间形式的1,3-偶极环加成反应†
    摘要:
    开发了I 2 -TBHP催化的偶氮甲亚胺亚胺和随后的具有芳香族N-杂环的区域选择性1,3-偶极环加成(DC),以优异的产率提供了各种4,3-稠合的1,2,4-三唑。该方法操作简便且高效,具有宽泛的官能团耐受性。
    DOI:
    10.1039/c6ob01926a
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20150315197A1
    公开(公告)日:2015-11-05
    The present invention provides a compound having the structure: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1 , R 2 , R 3 , R 4 , or R 5 are other than H; R 6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3 , R 3 is H, R 4 is CF 3 , and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3 , R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基,其中R1、R2、R3、R4或R5中的两个或更多个不是H;R6为H、OH或卤素;B为取代或未取代的杂环,其中当R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为H、R2为CF3、R3为H、R4为CF3和R5为H,或者R1为Cl、R2为H、R3为H、R4为F和R5为H,或者R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为CF3、R2为F、R3为H、R4为H和R5为H,或者R1为Cl、R2为F、R3为H、R4为H和R5为H时,则B不是或其药学上可接受的盐。
  • OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160024007A1
    公开(公告)日:2016-01-28
    The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    本发明提供了八氢环戊吡咯化合物,其结构如下:(结构式表示),其中psi不存在或存在,当存在时为键;R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基;R6不存在或存在,当存在时为H、OH或卤素;A不存在或存在,当存在时为C(O)或C(O)NH;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为C(O);当psi存在时,R6不存在,当psi不存在时,R6存在,或其药学上可接受的盐,用于治疗以视网膜过多脂褐质沉积为特征的疾病。
  • OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046632A1
    公开(公告)日:2016-02-18
    The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    本发明提供了包含各种取代的八氢吡咯吡咯化合物,它们的合成方法,制备方法,使用方法,以及它们的组成和配方。
  • N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046649A1
    公开(公告)日:2016-02-18
    The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:(结构表示)其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基;R6为烷基;A不存在或存在,当存在时为—C(O)—或—C(O)NH—;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为—C(O)—,或其药学上可接受的盐。
  • 4-phenylpiperidines, their preparation and use
    申请人:The Trustees of Columbia University in the City of New York
    公开号:US10273243B2
    公开(公告)日:2019-04-30
    The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:(结构表示),其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基;R6 为 H、OH 或卤素;B 为取代或未取代的杂环、哒嗪、吡唑、吡嗪、噻二唑或三唑,其中杂环为氯取代的吲哚以外的杂环;吡唑取代时为三氟甲基以外的取代基,或其药学上可接受的盐。
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶 8-溴-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-溴-[1,2,4]三氮唑并[4,3-A]吡啶 8-溴-[1,2,4]三唑并[1,5-A]吡啶 8-溴-[1,2,4]三唑[4,3-a]吡啶-6-羧酸 8-溴-6-氯-2-甲基-[1,2,4]噻唑并[1,5-a]吡啶